Loading...
•
Jun 30, 2021
Mersana Q2 2021 Earnings Report
Mersana reported financial results for the second quarter ended June 30, 2021 and provided a business update.
Key Takeaways
Mersana Therapeutics reported cash and cash equivalents of $227.4 million as of June 30, 2021. Net cash used in operating activities in the second quarter of 2021 was $34.5 million. The Company expects that its available funds will be sufficient to support its operating plan commitments for approximately two years.
Upifitamab Rilsodotin (UpRi) is a first-in-class Dolaflexin ADC targeting NaPi2b.
XMT-1592 is the first Dolasynthen ADC targeting NaPi2b.
XMT-1660 is a first-in-class Dolasynthen ADC targeting B7-H4.
XMT-2056 is the first Immunosynthen STING-agonist ADC.
Forward Guidance
The Company expects that its available funds will be sufficient to support its operating plan commitments for approximately two years.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...